bioMerieux (OTCMKTS:BMXMF) Given Consensus Recommendation of “Reduce” by Brokerages

bioMerieux (OTCMKTS:BMXMF) has been given a consensus recommendation of “Reduce” by the six analysts that are currently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation and five have assigned a hold recommendation to the company.

Several analysts recently commented on BMXMF shares. UBS Group lowered shares of bioMerieux from a “buy” rating to a “neutral” rating in a research report on Monday, June 1st. Deutsche Bank Aktiengesellschaft restated a “hold” rating on shares of bioMerieux in a research report on Wednesday, June 17th. Morgan Stanley lowered shares of bioMerieux from an “overweight” rating to an “underweight” rating in a research report on Tuesday, June 23rd. Piper Sandler began coverage on shares of bioMerieux in a research report on Thursday, June 11th. They set a “neutral” rating on the stock. Finally, Zacks Research upgraded shares of bioMerieux to a “hold” rating in a research report on Tuesday, April 28th.

bioMerieux Trading Up 0.7%

BMXMF stock opened at $79.87 on Tuesday. The company has a debt-to-equity ratio of 0.08, a quick ratio of 1.48 and a current ratio of 2.39. The firm’s fifty day moving average is $85.18 and its 200 day moving average is $105.83. bioMerieux has a one year low of $77.00 and a one year high of $152.00.

bioMerieux Company Profile

bioMérieux is a global leader in in vitro diagnostics, specializing in the development, manufacture and distribution of diagnostic solutions that determine the source of disease and contamination to improve patient health and ensure consumer safety. The company’s product portfolio encompasses a broad range of assays and instruments for microbiological and immunoassay testing, including molecular diagnostics for infectious diseases, immunoassays for autoimmune and oncology markers, and traditional microbial identification and antimicrobial susceptibility testing.